Leading Element Driving Change in the Giant-Cell Arteritis Market in 2025: Embracing Personalized Medicine A Shift Towards Tailored Healthcare Solutions Driver

What Is the Estimated Market Size and Growth Rate for the Giant-Cell Arteritis Market?
Over the past few years, the market size for giant-cell arteritis has boldly surged. The market, which is predicted to expand from $1.07 billion in 2024 to $1.12 billion in 2025 with a compound annual growth rate (CAGR) of 5.3%, has seen growth primarily due to the impact of epidemiological research, genetic understanding, rising use of biologics, enhancements in diagnostic methodologies, and advancement in targeted therapies and biologics.

The market size for giant-cell arteritis is projected to experience consistent expansion in the upcoming years. With a compound annual growth rate (CAGR) of 5.0%, the market is predicted to reach $1.36 billion by 2029. The driving factors behind this expansion during the forecast period are higher rates of diagnosis, an increasing elder population, amplified healthcare spending, patient advocacy, and growth into new geographical areas. Significant trends during this period will include breakthroughs in locating and certifying biomarkers, the progression of therapies that target specific molecular pathways, the employment of state-of-the-art imaging techniques, innovations in drug delivery, and the use of AI procedures for predictive analytics.

What Is Stimulating Growth in the Giant-Cell Arteritis Market?
The forward movement of the giant-cell arteritis market is predicted to be driven by the increasing focus on personalized medicine. This approach to healthcare is customised to individual characteristics like genetic makeup, lifestyle, and environment. Personalized medicine, boosted by advancements in genomics, biotechnology, and data analytics, provides targeted therapies that increase treatment efficiency and minimize undesired effects for patients. In the context of giant-cell arteritis (GCA), personalized medicine allows for therapies specifically designed based on unique patient factors such as genetic predispositions, immune reactions, and disease presentations. For example, in February 2024, the Personalized Medicine Coalition (PMC), a nonprofit organization based in the U.S., disclosed that more than a third of the new drug approvals by the U.S. Food and Drug Administration (FDA) for the fourth year in a row in 2023 were personalized medicines. In this year, the FDA greenlit 16 new personalized treatments for rare diseases, a marked leap from the six approvals in 2022. Furthermore, the approvals in 2023 also included seven cancer drugs and three treatments for a variety of other diseases and conditions. Thus, the rising focus on personalized medicine is fueling the expansion of the giant-cell arteritis market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

Who Are the Dominant Companies Influencing Giant-Cell Arteritis Market Trends?
Major companies operating in the giant-cell arteritis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Limited, Kiniksa Pharmaceuticals Ltd., MorphoSys AG

How Is the Giant-Cell Arteritis Market Evolving?
Leading firms within the giant-cell arteritis domain are introducing new products such as biosimilars, in a bid to fortify treatment options and respond to patients' unfulfilled medical requirements. A biosimilar refers to a biologic medication that bears a high resemblance to an existing approved biological product, devoid of any significant differences concerning safety, purity, and potency. For instance, in April 2024, Tocilizumab-aazg, a biosimilar, was launched in the US by Fresenius SE & Co. KGaA, a prominent healthcare organization based in Germany. The product is intended for the treatment of chronic autoimmune diseases and is approved for the treatment of conditions including rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. The approval of this biosimilar was backed by the results obtained from a randomised, double-blind, parallel phase 1 trial. This trial compared the pharmacokinetics, safety, and immunogenicity of the biosimilar to both US and EU reference tocilizumab across three distinct patient groups.

What Are the Different Segmentations in the Giant-Cell Arteritis Market?
The giant-cell arteritis market covered in this report is segmented -

1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin
2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action
3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:
1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy
2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy
3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids
4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Which Region Is at the Forefront of the Giant-Cell Arteritis Market?
North America was the largest region in the giant-cell arteritis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Giant-Cell Arteritis Global Market Report?

- Market Size Analysis: Analyze the Giant-Cell Arteritis Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Giant-Cell Arteritis Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Giant-Cell Arteritis Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Giant-Cell Arteritis Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17162

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.